Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Preclinical, early phase clinical trials and epidemiological evidence support the potential role of insulin-sensitizers in cancer prevention and treatment. Insulin-sensitizers improve the metabolic and hormonal profile in PCOS patients and may also act as anticancer agents, especially in cancers associated with hyperinsulinemia and oestrogen dependent cancers. Several lines of evidence support the protection against cancer exerted by dietary inositol, in particular inositol hexaphosphate. Metformin, thiazolidinediones, and myoinositol postreceptor signaling may exhibit direct inhibitory effects on cancer cell growth. AMPK, the main molecular target of metformin, is emerging as a target for cancer prevention and treatment. PCOS may be correlated to an increased risk for developing ovarian and endometrial cancer (up to threefold). Several studies have demonstrated an increase in mortality rate from ovarian cancer among overweight/obese PCOS women compared with normal weight women. Long-term use of metformin has been associated with lower rates of ovarian cancer. Considering the evidence supporting a higher risk of gynaecological cancer in PCOS women, we discuss the potential use of insulin-sensitizers as a potential tool for chemoprevention, hypothesizing a possible rationale through which insulin-sensitizers may inhibit tumourigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 2×
“through an increase of intracellular ADP : ATP ratio, which leads to the inhibition of respiratory chain and subsequent AMPK phosphorylation [62].”
BackgroundFauser, B. C. J. M., Tarlatzis, B. C., Rebar, R. W., Legro, R. S., Balen, A. H., Lobo, R., Carmina, E., Chang, J., Yildiz, B. O., Laven, J. S. E., et al. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.024 · Cited by 1,976 · cited 1×
“All these lines of evidence suggest, as stated by the 3rd PCOS Consensus Group [168], that there are moderate-quality data supporting the high risk of PCOS women for developing endometrial cancer, with consequent need for increased awareness for surveillance strategies.”
ResultThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“Furthermore, metformin plays an essential role in the inhibition of hepatic gluconeogenesis [169] with the consequent decrease in insulin levels.”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638 · cited 1×
“Myo-Ins is an important component of the structural lipids and its various phosphates, including the phosphatidylinositol phosphate (PIP) lipids [102–104], are essential inmaintaining the cellular membrane bilayer.”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“AMPK activation by metformin induces fatty acid oxidation, reduces lipid synthesis, and inhibits gluconeogenesis [63, 64].”
BackgroundManning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“The effects of metformin on glucose metabolism seem to be secondary to its actions on the mitochondrial respiratory chain, inhibiting themitochondrial respiratory complex I [61, 62].”
BackgroundPRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 1×
“It has been demonstrated that the insulin-activated kinase Akt phosphorylates TSC2 at distinct sites from those specific for AMPK, blocking its RHEB-GAP function [36, 43, 44], and also phosphorylates proline-rich Akt substrate of 40 kDa (PRAS40), enhancing its inhibitory effect on the mTORC1 complex [45].”
BackgroundMetabolism of Inflammation Limited by AMPK and Pseudo-Starvation
O'Neill, L. A. J., & Hardie, D. G. (2013) · Nature · doi:10.1038/nature11862 · Cited by 1,133
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115 · cited 1×
“In particular, it was shown that its use in a subpopulation of breast cancer cells suppressed their growth and decreased the ability of these cells to form tumours in mice [77]; its combinationwith trastuzumab leads to a reduction of cancerinitiating cell population in Her2-amplified breast cancer cells [78].”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“in a retrospective study of 2529 diabetic patients, including 68 on metformin and 87 not, showed that diabetic patients affected with breast cancer and treated with metformin had higher rates of complete response to neoadjuvant chemotherapy than those not taking metformin [73].”
BackgroundJoost, H.-G., & Thorens, B. (2001) · Molecular Membrane Biology · doi:10.1080/09687680110090456 · Cited by 719
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 1×
“As mentioned above, PCOS is characterized by metabolic features such as central obesity and insulin resistance with compensatory hyperinsulinemia that also are key factors in the pathogenesis of chronic anovulation [111–113].”
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
Metformin reduces endogenous reactive oxygen species and associated DNA damage
Algire, C., Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., Viollet, B., Ferbeyre, G., & Pollak, M. N. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0536 · Cited by 372 · cited 1×
“A study in vitro has shown that it significantly reduces DNA damage and mutation rates [72]; this might be the explanation of the reduced risk of cancer that has been shown by many epidemiological studies through the use of metformin.”
BackgroundSakamoto, K., Göransson, O., Hardie, D. G., & Alessi, D. R. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00074.2004 · Cited by 299 · cited 1×
“This complex is constitutively active and presents a high basal activity [29]; however its ability to phosphorylate Thr172 is improved by conformational changes in its AMPK substrate, due to the binding of 5 adenosine monophosphate (AMP) active to its γ-subunit.”
BackgroundAMP ‐activated protein kinase: a key regulator of energy balance with many roles in human disease
Grahame Hardie, D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12268 · Cited by 285
Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
LeBrasseur, N. K., Kelly, M., Tsao, T.-S., Farmer, S. R., Saha, A. K., Ruderman, N. B., & Tomas, E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2005 · Cited by 276
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · cited 1×
“In addition to this, due to the lack of studies, a systematic review carried out using the Cochrane Library database [178] did not reach any firm conclusion about a preventive role of metformin in endometrial cancer.”
BackgroundThe management of patients with polycystic ovary syndrome
Jayasena, C. N., & Franks, S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.102 · Cited by 196
Differential regulation by AMP and ADP of AMPK complexes containing different γ subunit isoforms
Ross, F. A., Jensen, T. E., & Hardie, D. G. (2016) · Biochemical Journal · doi:10.1042/bj20150910 · Cited by 172
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154 · cited 2×
“The main risk factors regarding hormone-related cancer are recognized in exposure to unopposed estrogen therapy, overweight and obesity, late-age menopause, and nulliparity [114, 115] and therapy with Tamoxifen as well [154].”
BackgroundSarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061537 · Cited by 150 · cited 1×
“Thus, a pivotal biological pathway leading to endometrial cancermay be theoretically controlled by metformin, to reduce the risk of EH progression [174].”
BackgroundInositol Polyphosphate Multikinase Is a Physiologic PI3-Kinase That Activates Akt/PKB
Maag, D., Maxwell, M. J., Hardesty, D. A., Boucher, K. L., Choudhari, N., Hanno, A. G., Ma, J. F., Snowman, A. S., Pietropaoli, J. W., Xu, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017831108 · Cited by 122
Schneider, S. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.03.012 · Cited by 118 · cited 1×
“Inositol transporters are involved in uptake and intracellular distribution of inositols that, according to their transport mechanism, can be classified as sodium ion coupled and proton coupled inositol transporters [96].”
Background
Cited by
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Self-citationAl Wattar, B. H., Bueno, A., Martin, M. G., Ibáñez, N. C., Harasani, K., Garad, R., Franks, S., Balen, A., Bhide, P., Piltonen, T., et al. (2021) · Human Reproduction · doi:10.1093/humrep/deaa331 · Cited by 14
“Epidemiological studies helped to crystallize the risk of endometrial cancer in this group and prompted the introduction of preventative treatments into routine care (Lauretta et al., 2016; MacKintosh and Crosbie, 2018).”
Background
Metadata
- Authors
- Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., & Appetecchia, M.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-17
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W2521297707
- Cited by
- 36
- References
- 34
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.